IL114458A0 - Therapeutic preparations for treatment of T cell mediated diseases - Google Patents

Therapeutic preparations for treatment of T cell mediated diseases

Info

Publication number
IL114458A0
IL114458A0 IL11445895A IL11445895A IL114458A0 IL 114458 A0 IL114458 A0 IL 114458A0 IL 11445895 A IL11445895 A IL 11445895A IL 11445895 A IL11445895 A IL 11445895A IL 114458 A0 IL114458 A0 IL 114458A0
Authority
IL
Israel
Prior art keywords
cell mediated
treatment
mediated diseases
therapeutic preparations
condition
Prior art date
Application number
IL11445895A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11445895A priority Critical patent/IL114458A0/xx
Publication of IL114458A0 publication Critical patent/IL114458A0/xx
Priority to SI9630662T priority patent/SI0837672T1/xx
Priority to IL12275596A priority patent/IL122755A/en
Priority to EP96924371A priority patent/EP0837672B9/en
Priority to ES96924371T priority patent/ES2211963T3/es
Priority to PT96924371T priority patent/PT837672E/pt
Priority to KR10-1998-0700036A priority patent/KR100435040B1/ko
Priority to CN96196402A priority patent/CN1102382C/zh
Priority to DE69630787T priority patent/DE69630787T2/de
Priority to MX9800190A priority patent/MX9800190A/es
Priority to US08/981,861 priority patent/US6488933B2/en
Priority to CZ982A priority patent/CZ298A3/cs
Priority to HU9802834A priority patent/HU223081B1/hu
Priority to DK96924371T priority patent/DK0837672T3/da
Priority to AU64844/96A priority patent/AU714970B2/en
Priority to PCT/US1996/011373 priority patent/WO1997002016A1/en
Priority to AT96924371T priority patent/ATE254451T1/de
Priority to CA2226013A priority patent/CA2226013C/en
Priority to JP50531797A priority patent/JP4357595B2/ja
Priority to ZA965666A priority patent/ZA965666B/xx
Priority to HR114458A priority patent/HRP960315A2/hr
Priority to UY24275A priority patent/UY24275A1/es
Priority to YU40796A priority patent/YU40796A/sh
Priority to NO19980013A priority patent/NO320363B1/no
Priority to US10/307,326 priority patent/US20030190323A1/en
Priority to JP2009141914A priority patent/JP2009242412A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Rehabilitation Therapy (AREA)
IL11445895A 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases IL114458A0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases
JP50531797A JP4357595B2 (ja) 1995-07-05 1996-07-02 Ｔ細胞介在の病気を治療するための製剤と方法
HU9802834A HU223081B1 (hu) 1995-07-05 1996-07-02 T-sejt által közvetített autoimmun betegségek kezelésére szolgáló készítmények
AU64844/96A AU714970B2 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of T cell mediated diseases
EP96924371A EP0837672B9 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases
ES96924371T ES2211963T3 (es) 1995-07-05 1996-07-02 Preparaciones y procedimientos para el tratamiento de enfermedades mediadas por celulas t.
PT96924371T PT837672E (pt) 1995-07-05 1996-07-02 Preparacoes e metodos para o tratamento de doencas mediadas por celulas t
KR10-1998-0700036A KR100435040B1 (ko) 1995-07-05 1996-07-02 티세포매개성질환들의치료를위한제제들및방법들
CN96196402A CN1102382C (zh) 1995-07-05 1996-07-02 用于治疗t细胞介导疾病的制剂与方法
DE69630787T DE69630787T2 (de) 1995-07-05 1996-07-02 Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten
MX9800190A MX9800190A (es) 1995-07-05 1996-07-02 Preparaciones y metodos para el tratamiento de enfermedades mediadas por celulas t.
US08/981,861 US6488933B2 (en) 1995-07-05 1996-07-02 Preparations for the treatment of T cell mediated diseases
CZ982A CZ298A3 (cs) 1995-07-05 1996-07-02 Přípravky a způsoby ošetřování nemocí zprostředkovanými T buňkami
SI9630662T SI0837672T1 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases
DK96924371T DK0837672T3 (da) 1995-07-05 1996-07-02 Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
IL12275596A IL122755A (en) 1995-07-05 1996-07-02 Preparations for the treatment of t cell mediated diseases
PCT/US1996/011373 WO1997002016A1 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases
AT96924371T ATE254451T1 (de) 1995-07-05 1996-07-02 Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten
CA2226013A CA2226013C (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases
HR114458A HRP960315A2 (en) 1995-07-05 1996-07-04 Preparations and methods for the treatment of t cell mediated diseases
ZA965666A ZA965666B (en) 1995-07-05 1996-07-04 Preparations and methods for the treatment of t cell mediated diseases
UY24275A UY24275A1 (es) 1995-07-05 1996-07-05 Preparaciones y métodos para el tratamiento de enfermedades provocadas por las células t.
YU40796A YU40796A (sh) 1995-07-05 1996-07-05 Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
NO19980013A NO320363B1 (no) 1995-07-05 1998-01-02 Preparater for behandling av T-cellemedierte autoimmune sykdommer og anvendelse av en fettemulsjon som biologisk aktiv baerer.
US10/307,326 US20030190323A1 (en) 1995-07-05 2002-12-02 Preparations and methods for the treatment of T cell mediated diseases
JP2009141914A JP2009242412A (ja) 1995-07-05 2009-06-15 Ｔ細胞介在の病気を治療するための製剤と方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases

Publications (1)

Publication Number Publication Date
IL114458A0 true IL114458A0 (en) 1995-11-27

Family

ID=11067727

Family Applications (2)

Application Number Title Priority Date Filing Date
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases
IL12275596A IL122755A (en) 1995-07-05 1996-07-02 Preparations for the treatment of t cell mediated diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12275596A IL122755A (en) 1995-07-05 1996-07-02 Preparations for the treatment of t cell mediated diseases

Country Status (22)

Country Link
EP (1) EP0837672B9 (ko)
JP (2) JP4357595B2 (ko)
KR (1) KR100435040B1 (ko)
CN (1) CN1102382C (ko)
AT (1) ATE254451T1 (ko)
AU (1) AU714970B2 (ko)
CA (1) CA2226013C (ko)
CZ (1) CZ298A3 (ko)
DE (1) DE69630787T2 (ko)
DK (1) DK0837672T3 (ko)
ES (1) ES2211963T3 (ko)
HR (1) HRP960315A2 (ko)
HU (1) HU223081B1 (ko)
IL (2) IL114458A0 (ko)
MX (1) MX9800190A (ko)
NO (1) NO320363B1 (ko)
PT (1) PT837672E (ko)
SI (1) SI0837672T1 (ko)
UY (1) UY24275A1 (ko)
WO (1) WO1997002016A1 (ko)
YU (1) YU40796A (ko)
ZA (1) ZA965666B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
EP2301566B1 (en) 2002-05-21 2013-07-03 Irun R. Cohen DNA vaccines encoding heat shock proteins
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
CA2547079A1 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, PEPTIDES HSP60 AND T-CELL VACCINES FOR IMMUNOMODULATION
JP2009508517A (ja) 2005-09-22 2009-03-05 コーエン，イルン，アール Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
KR100435040B1 (ko) 2004-08-18
CA2226013C (en) 2012-09-18
WO1997002016A1 (en) 1997-01-23
PT837672E (pt) 2004-03-31
YU40796A (sh) 1998-11-05
SI0837672T1 (en) 2004-04-30
JP4357595B2 (ja) 2009-11-04
DE69630787T2 (de) 2004-10-07
DE69630787D1 (de) 2003-12-24
MX9800190A (es) 1998-04-30
ZA965666B (en) 1997-01-27
AU6484496A (en) 1997-02-05
JP2009242412A (ja) 2009-10-22
AU714970B2 (en) 2000-01-13
EP0837672B9 (en) 2005-06-15
UY24275A1 (es) 2000-12-29
HU223081B1 (hu) 2004-03-29
NO320363B1 (no) 2005-11-28
IL122755A0 (en) 1998-08-16
JPH11508899A (ja) 1999-08-03
CN1193907A (zh) 1998-09-23
CN1102382C (zh) 2003-03-05
EP0837672B1 (en) 2003-11-19
DK0837672T3 (da) 2004-03-22
ATE254451T1 (de) 2003-12-15
HUP9802834A2 (hu) 1999-03-29
NO980013L (no) 1998-02-19
CZ298A3 (cs) 1998-06-17
NO980013D0 (no) 1998-01-02
IL122755A (en) 2004-07-25
CA2226013A1 (en) 1997-01-23
ES2211963T3 (es) 2004-07-16
EP0837672A1 (en) 1998-04-29
KR19990028738A (ko) 1999-04-15
HUP9802834A3 (en) 2001-08-28
EP0837672A4 (en) 1999-01-27
HRP960315A2 (en) 1998-02-28

Similar Documents

Publication Publication Date Title
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
IL114458A0 (en) Therapeutic preparations for treatment of T cell mediated diseases
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
CA2078235A1 (en) Idiotypic vaccination against b cell lymphoma
PT879056E (pt) Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
WO2002012286A3 (en) Stress proteins and peptides and methods of use thereof
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
HUP9901077A2 (hu) Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
Wrigley et al. Normal cerebral function with bilateral carotid occlusion.
Rees et al. Glossopharyngeal neuralgia with syncope.
UA28518A (uk) Спосіб визначення алергену у хворих на лікарську хворобу
EP1052285A3 (en) Method of inducing an antigen-specific anticytotoxic cell
O'Brien Premenstrual tension syndrome.
Plana Tematica delirante psicotica en psicopatologia de la expresion pictoria. Mitologemas.
Aonuma et al. Studies on biologically active substances formed by Bacilli. V. Removal of surface active factor and lipids from the serum calcium decreasing substance alpha-factor produced by B. subtilis K (author's transl)
ES2183376T3 (es) Uso de lbp para el tratamiento de la septicemia.
Robinson Epilepsy and learning.
Dorr Modulatory effects of cimetidine on the bovine immune system: Cell-mediated immunity, suppressor cell function and immunoglobulin-E production.
UA6640A (uk) Спосіб прогнозування загострення супутнього захворювання при активізації основної патології